Supernus Pharmaceuticals Long Term Debt

Supernus Pharmaceuticals (SUPN) currently reports a long-term debt of $29M as of June 2026. That compares with $49M in the prior-year period — down 39.7% year over year. Use the charts on this page to explore Supernus Pharmaceuticals's long-term debt history and peer comparisons.

Supernus Pharmaceuticals's long-term debt decreased from $49M to $29M — a 39.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Supernus Pharmaceuticals reported $29M in long-term debt as of June 2026. That compares with $49M in the prior-year period — down 39.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $29M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Supernus Pharmaceuticals, and consider following SUPN for alerts when major investors trade the stock.

Supernus Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $29M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SUPN with unrelated industries.